Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Type 1 or type 2 diabetes mellitus~2. BCVA ETDRS \> 20/400 in the study eye~3. Willing and able to comply with clinic visits and study-related procedures~4. Provide signed informed consent~5. Substantial non perfusion (defined as greater than 20 disc areas), as assessed by the investigator~6. Early PDR, as assessed by the investigator, with no vitreous hemorrhage\*~   * Early PDR is defined in which PRP can safely be deferred and vitreous hemorrhage that does not obscure the application of PRP~Exclusion Criteria:~1. Any prior systemic anti-VEGF (anti vascular endothelial growth factor) or IVT anti-VEGF treatment in the study eye,~2. SD-OCT (Spectral Domain Optical Coherence Tomography) central subfield thickness measurement of \> 320 µm, in the study eye~3. Evidence of infectious ocular infection, in the study eye, at time of screening~4. History of vitreoretinal surgery in the study eye~5. Any prior Panretinal laser photocoagulation (PRP) in the study eye~6. Current vitreous hemorrhage obscuring retinal imaging in the study eye~7. Cataract surgery in the study eye within 4 weeks of Day 0~8. Uncontrolled blood pressure (defined as \> 180/110 mm Hg systolic/diastolic, while seated)~9. Significant renal disease defined as a history of chronic renal failure requiring dialysis or renal transplant~10. Tractional Retinal Detachment threatening the macula in the study eye~11. Corticosteroid treatment (intravitreal or peribulbar) in the study eye within 12 weeks of screening~12. Pregnant or breast-feeding women~13. Sexually active men\* or women of childbearing potential who are unwilling to practice adequate contraception during the study. Adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device (IUD); bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly.~    * Contraception is not required for men with documented vasectomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Q4WKS (Type: EXPERIMENTAL): Aflibercept 2 mg every 4 weeks (defined as every 28 days (+ 7 days) and at least 21 days between injections) through week 48. Following week 48, aflibercept 2 mg every 12 weeks through week 96.~If NV or PDR are worse per pre-specified criteria at week 60, or at any study visit thereafter, the subject will be treated every 4 weeks through the end of the study.
- Q12WKS (Type: EXPERIMENTAL): Aflibercept 2 mg every 12-weeks. Subjects will be followed every 4 weeks through week 12, and can be treated if the pre-specified criteria are met. Starting at week 12 if NV or PDR are stable or improved (as assessed by investigator) the subject will be monitored and treated at a 12-week interval through week 48. If NV or PDR are worse per the pre-specified criteria at week 12, or at any study visit thereafter, the subject will be treated monthly through the end of the study.~At week 52, aflibercept 2 mg every 4 weeks (defined as 28 days (+ 7 days) and at least 21 days between injections) for subjects with visible retinal non-perfusion. If retinal non-perfusion has completely resolved at week 72, aflibercept every 12 weeks through end of study. For subjects without retinal non-perfusion at week 52, aflibercept 2 mg every 12 weeks through the end of study.

Based on this trial design, predict the completion outcome and termination type (if applicable).